NPC-09: Phase III started

Ultragenyx began a double-blind, placebo-controlled, international Phase III trial to evaluate 6 g/day Ace-ER for 48 weeks in about 80 patients. Ultragenyx has exclusive rights to Ace-ER outside of Ja...